Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
- DOI
- 10.1182/blood-2006-07-035493
- Published
- 2006-09-21
- Container
- Blood
- Publisher
- American Society of Hematology
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1182/blood-2006-07-035493,
title = {Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure},
author = {Alfonso Quintas-Cardama and Hagop Kantarjian and Dan Jones and Claude Nicaise and Susan O'Brien and Francis Giles and Moshe Talpaz and Jorge Cortes},
year = {2006},
journal = {Blood},
doi = {10.1182/blood-2006-07-035493},
url = {https://doi.org/10.1182/blood-2006-07-035493}
}RIS
TY - JOUR TI - Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure AU - Alfonso Quintas-Cardama AU - Hagop Kantarjian AU - Dan Jones AU - Claude Nicaise AU - Susan O'Brien AU - Francis Giles AU - Moshe Talpaz AU - Jorge Cortes PY - 2006 JO - Blood DO - 10.1182/blood-2006-07-035493 UR - https://doi.org/10.1182/blood-2006-07-035493 ER -
APA
Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'Brien, S., Giles, F., Talpaz, M., & Cortes, J. (2006). Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. https://doi.org/10.1182/blood-2006-07-035493
Source records
- crossref · retrieved 2026-09-26T04:51:57.397Z